首页> American Journal of Kidney Diseases: The official journal of the National Kidney Foundation> Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial

Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial

导出原文传递

翻译打印收藏纠错

第一作者： Gansevoort R.T.

作者： Gansevoort R.T. ^[1] ; Hariri A. ^[2] ; Minini P. ^[3] ; Ahn C. ^[4] ; Chapman A.B. ^[5] ; Horie S. ^[6] ; Knebelmann B. ^[7] ; Mrug M. ^[8] ; Ong A.C.M. ^[9] ; Pei Y.P.C. ^[10] ; Torres V.E. ^[11] ; Modur V. ^[12] ; Antonshchuk I. ; Perrone R.D.

作者单位： Division of Nephrology University of Toronto ^[1] Division of Nephrology and Hypertension Mayo Clinic ^[2] Eloxx Pharmaceuticals ^[3] Sanofi Chilly-Mazarin ^[4] Division of Nephrology Tufts Medical Center Tufts University School of Medicine ^[5] Department of Nephrology University Medical Center Groningen ^[6] Department of Internal Medicine Seoul National University ^[7] Department of Medicine University of Chicago ^[8] Department of Urology Juntendo University Graduate School of Medicine ^[9] Université Paris Cité AP-HP Service de Néphrologie H?pital Necker-Enfants Malades ^[10] Department of Medicine University of Alabama at Birmingham ^[11] Academic Nephrology Unit Department of Infection Immunity and Cardiovascular Disease University of ^[12]

关键词 Autosomal dominant polycystic kidney disease (ADPKD)cysts eGFR decline estimated glomerular filtration rate (eGFR)glucosylceramide (GL-1)randomized clinical trial (RCT)renal function total kidney volume (TKV)venglustat

发布时间 2023-06-13

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交